Compare Duolingo Inc (DUOL) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Nuwellis Inc — how do they compare? Duolingo Inc trades at $151.56 (market cap $7.08B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Duolingo Inc is far larger — about 3218.2× Nuwellis Inc's market cap, and Duolingo Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Nuwellis Inc for 26 Days on average.
| DUOL | NUWE | |
|---|---|---|
Market Cap | $7.08B | $2.20M |
Volume | 729,171 | 121,544 |
Sector | Technology | Health |
52-Week High | $341.08 | $146.65 |
52-Week Low | $90.03 | $0.68 |
Typical Hold Time | 137 Days | 26 Days |
Enterprise Value | $5.85B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $151.72, up 2.42% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $369M in 2022 to $1.04B in 2025 and net income surging to $414M. Recent earnings consistently beat expectations, though Q3 2026 results are pending. Analyst consensus is mixed with 37.5% buy ratings but a $140.63 price target below current levels. Operating cash flow reached $388M in 2025, supporting continued investment in user growth and AI capabilities.
Duolingo presents growth potential through AI-driven expansion and strong user metrics, but faces risks from insider selling and valuation concerns. The stock's current price exceeds analyst consensus, suggesting limited near-term upside. Key opportunities include market expansion beyond language learning, while risks involve competitive pressures and execution on monetization strategies.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
